Inluriyo Tablet, Film Coated
NDC Package 0002-1717-28

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Inluriyo (imlunestrant) tablets is iNLURIYO is indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. This formulation utilizes a tablet, film coated delivery system. Marketed by Eli Lilly And Company, this product is identified by NDC 0002-1717 and is authorized under FDA application NDA218881.

Identification & Billing

NDC Package Code
0002-1717-28
Package Description
28 TABLET, FILM COATED in 1 BOTTLE
Product Code
0002-1717
11-Digit Billing Format
00002171728
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
28 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Inluriyo
Non-Proprietary Name
Imlunestrant
Substance Name
Imlunestrant
Dosage Form
Tablet, Film Coated - A solid dosage form that contains medicinal substances with or without suitable diluents and is coated with a thin layer of a water-insoluble or water-soluble polymer.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
IMLUNESTRANT 200 mg/1
Pharmacologic Class
Usage Information
INLURIYO is indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.

Regulatory & Marketing

Labeler Name
Eli Lilly And Company
Product Type
Human Prescription Drug
FDA Application #
NDA218881
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
09-25-2025
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (0002-1717). Click a package code to view its specific billing and regulatory data.

0002-1717-56
56 TABLET, FILM COATED in 1 BOTTLE
0002-1717-61
56 TABLET, FILM COATED in 1 BOTTLE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0002-1717-28 identifies a specific commercial package of 28 tablet, film coated in 1 bottle of Inluriyo, a human prescription drug labeled by Eli Lilly And Company. This product is billed for "EA" each discreet unit and contains an estimated amount of 28 billable units per package. This tablet, film coated is formulated for oral use and contains imlunestrant as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Eli Lilly And Company on September 25, 2025. The current certification is valid through December 31, 2027.

How is this Eli Lilly And Company product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00002171728. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 28 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0002-1717-28
11-Digit CMS (5-4-2)
00002-1717-28

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.